The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation for uterus-limited, high-grade leiomyosarcoma: A phase III GOG study.
 
Martee Leigh Hensley
Employment - Sanofi (I)
Stock and Other Ownership Interests - Sanofi (I)
Consulting or Advisory Role - EMD Serono; Janssen; Janssen; Janssen; Janssen; Lilly; Lilly; Onclive; Tesaro
Research Funding - Bristol-Myers Squibb (Inst); Johnson & Johnson (Inst)
Patents, Royalties, Other Intellectual Property - author, Up to Date
 
Danielle Enserro
No Relationships to Disclose
 
Helen Hatcher
No Relationships to Disclose
 
P. B. Ottevanger
Research Funding - Novartis (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - MSD; Roche
 
Anders Krarup-Hansen
No Relationships to Disclose
 
Jean-Yves Blay
Honoraria - Bayer; GlaxoSmithKline; Lilly; Novartis; Pharmamar; Roche
Consulting or Advisory Role - Bayer; GlaxoSmithKline; Merck; Novartis; PharmaMar; Roche
Research Funding - Bayer (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pharmamar (Inst); Roche (Inst)
Other Relationship - Innate Pharma
 
Cyril Fisher
No Relationships to Disclose
 
Katherine M. Moxley
No Relationships to Disclose
 
Shashikant B. Lele
No Relationships to Disclose
 
Jayanthi Sivasothy Lea
No Relationships to Disclose
 
Krishnansu Sujata Tewari
Consulting or Advisory Role - Roche/Genentech
Speakers' Bureau - AstraZeneca; Merck; Roche/Genentech
Travel, Accommodations, Expenses - Roche/Genentech
 
Premal H. Thaker
No Relationships to Disclose
 
Oliver Zivanovic
No Relationships to Disclose
 
David M. O'Malley
Honoraria - Clovis Oncology
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Clovis Oncology; Janssen Oncology; Myriad Genetics; Novocure; Tesaro
Research Funding - Agenus (Inst); Ajinomoto (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Clovis Oncology (Inst); EMD Serono (Inst); Ergomed (Inst); Genentech/Roche (Inst); Immunogen (Inst); Immunogen (Inst); Janssen Research & Development (Inst); PharmaMar (Inst); Regeneron (Inst); Stem CentRx (Inst); Tesaro (Inst); TRACON Pharma (Inst); VentiRx (Inst)
 
Katina Robison
No Relationships to Disclose
 
David S. Miller
Consulting or Advisory Role - Alexion Pharmaceuticals; AstraZeneca; Clovis Oncology; Eisai; Genentech; Guardant Health; ImmunoGen; Tesaro
Speakers' Bureau - Clovis Oncology; Genentech
Research Funding - Aeterna Zentaris (Inst); Aprea AB (Inst); AstraZeneca (Inst); Genentech (Inst); ImmunoGen (Inst); Janssen (Inst); Pfizer (Inst); Takeda (Inst); Tesaro (Inst); TRACON Pharma (Inst); Xenetic Biosciences (Inst)